Public record
Batch Watch
What the public record says about research-peptide vendors and batches, as it happens: independent tests that did not meet a published standard, vendors whose status changed, and every batch of ours that a laboratory certified. Each entry quotes a named source and links it. We characterise nothing.
Showing the last 120 days. Our full certificate history, including every batch older than that, is published at certificates of analysis.
Buying? Every Lyra Vital product links its own certificates, and each certificate page shows which lot covers each size. Shop or see the lab reports in our own name.
Alerts by email
One message a week with the entries added since the last, nothing else. No discount codes, no product pushes. Unsubscribe in one click.
Fri, Nov 13, 2026
- Daily count
Finnrick published 1 test on 2026-11-13: 0 met the public standard, 0 did not
On 2026-11-13 Finnrick published 1 independent laboratory test across its vendor record. 0 met its public Purity Focus standard, 0 did not, 1 could not be classified. Every result is public on Finnrick with the laboratory certificate behind it.
Tue, Nov 10, 2026
- Did not meet standard
Retatrutide from China Peptides Supplier did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from China Peptides Supplier (stated 30 mg, batch RET-26031501) tested 10 Nov 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Pura Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Pura Peptides (stated 40 mg, batch RT40BTU-5126) tested 10 Nov 2026 at Harrens Lab: purity 66.2%, measured 26.48 mg (-34% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from China Peptides Supplier did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from China Peptides Supplier (stated 40 mg, batch RET-26031501) tested 10 Nov 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Junli Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Junli Peptide (stated 10 mg, batch 20261011) tested 10 Nov 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from Hangzhou Mandy Biotechnology did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Hangzhou Mandy Biotechnology (stated 60 mg, batch no lot in label) tested 10 Nov 2026 at Harrens Lab: purity 96.1%, measured 57.66 mg (-4% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from China Peptides Supplier did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from China Peptides Supplier (stated 40 mg, batch TRD-26031301) tested 10 Nov 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from China Peptides Supplier did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from China Peptides Supplier (stated 20 mg, batch TRD-26031301) tested 10 Nov 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Pura Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Pura Peptides (stated 40 mg, batch RT40U-71626) tested 10 Nov 2026 at Harrens Lab: purity 66.8%, measured 26.71 mg (-33% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Shenzhen Nuoao Technology did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Shenzhen Nuoao Technology (stated 15 mg, batch 2026.6.4) tested 10 Nov 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from China Peptides Supplier did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from China Peptides Supplier (stated 30 mg, batch TRD-26031301) tested 10 Nov 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from Xingtai Jiachuang Technology did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Xingtai Jiachuang Technology (stated 30 mg, batch No:01261014130X) tested 10 Nov 2026 at PharmLabs: purity 99.99%, measured 44.02 mg (+47% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Nanjing Peptide Biotechnology did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Nanjing Peptide Biotechnology (stated 20 mg, batch 20261011) tested 10 Nov 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Purely Pep Lab did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Purely Pep Lab (stated 20 mg, batch MBVP5761) tested 10 Nov 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Shijiazhuang Xindong Technology Service did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Shijiazhuang Xindong Technology Service (stated 30 mg, batch Mfg: June 2026) tested 10 Nov 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from SaiyanMed did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from SaiyanMed (stated 30 mg) tested 10 Nov 2026 at Harrens Lab: purity 64.7%, measured 19.41 mg (-35% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Daily count
Finnrick published 42 tests on 2026-11-10: 26 met the public standard, 15 did not
On 2026-11-10 Finnrick published 42 independent laboratory tests across its vendor record. 26 met its public Purity Focus standard, 15 did not, 1 could not be classified. Every result is public on Finnrick with the laboratory certificate behind it.
Mon, Nov 9, 2026
- Did not meet standard
SS-31 from Reta-Peptide did not meet Finnrick's public standard
Finnrick's public record lists a SS-31 sample from Reta-Peptide (stated 10 mg, batch 09/03/2026) tested 9 Nov 2026 at Krause Analytical: purity 99.4%, measured 10.9 mg (+9% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from Direct Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Direct Peptides (stated 10 mg, batch DPS-6373036) tested 9 Nov 2026 at Krause Analytical: purity 99.9%, measured 6.4 mg (-36% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
KLOW from Peptide Pole Hongkong did not meet Finnrick's public standard
Finnrick's public record lists a KLOW sample from Peptide Pole Hongkong (stated 80 mg, batch TG0912-53) tested 9 Nov 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Daily count
Finnrick published 32 tests on 2026-11-09: 27 met the public standard, 3 did not
On 2026-11-09 Finnrick published 32 independent laboratory tests across its vendor record. 27 met its public Purity Focus standard, 3 did not, 2 could not be classified. Every result is public on Finnrick with the laboratory certificate behind it.
Fri, Nov 6, 2026
- Did not meet standard
Tirzepatide from Inno Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Inno Peptides (stated 30 mg, batch Mfg 082426) tested 6 Nov 2026 at Harrens Lab: purity 40.7%, measured 12.22 mg (-59% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from Shanghai Leader Peptide Biotechnology did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Shanghai Leader Peptide Biotechnology (stated 30 mg, batch 09/15/2026) tested 6 Nov 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 30 mg, batch Sept 2028) tested 6 Nov 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from Inno Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Inno Peptides (stated 30 mg, batch LOT 2002030) tested 6 Nov 2026 at Harrens Lab: purity 32.5%, measured 9.74 mg (-68% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from Shanghai JinBei Chemical Technology did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Shanghai JinBei Chemical Technology (stated 30 mg) tested 6 Nov 2026 at Harrens Lab: purity 49.4%, measured 14.81 mg (-51% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from Oupeptide did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Oupeptide (stated 60 mg, batch 8608-13) tested 6 Nov 2026 at PharmLabs: purity 94.48%, measured 67.49 mg (+12% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tesamorelin from Inno Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Tesamorelin sample from Inno Peptides (stated 5 mg, batch MFG AUG 24 2026) tested 6 Nov 2026 at Harrens Lab: purity 15%, measured 1.5 mg (-70% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tesamorelin→
- Did not meet standard
Retatrutide from Cytlink did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Cytlink (stated 5 mg, batch N/A Pink Top) tested 6 Nov 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from Sennuo Community did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Sennuo Community (stated 60 mg, batch aug,27,2026 vexo research) tested 6 Nov 2026 at Harrens Lab: purity 75.6%, measured 45.37 mg (-24% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Daily count
Finnrick published 35 tests on 2026-11-06: 24 met the public standard, 9 did not
On 2026-11-06 Finnrick published 35 independent laboratory tests across its vendor record. 24 met its public Purity Focus standard, 9 did not, 2 could not be classified. Every result is public on Finnrick with the laboratory certificate behind it.
Thu, Nov 5, 2026
- Did not meet standard
Retatrutide from Lumira did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Lumira (stated 5 mg, batch Wp- -p00043) tested 5 Nov 2026 at BTLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from Shandong Aishi Biotechnology did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Shandong Aishi Biotechnology (stated 5 mg, batch March 2, 2026) tested 5 Nov 2026 at BTLabs: purity 91.2%, measured 4.9 mg (-2% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Sulan Pharma did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Sulan Pharma (stated 10 mg, batch July 2026) tested 5 Nov 2026 at BTLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from Reta-Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Reta-Peptide (stated 10 mg, batch Aug 30, 2026) tested 5 Nov 2026 at BTLabs: purity 92.9%, measured 9.4 mg (-6% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from YH Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from YH Peptide (stated 10 mg, batch Mfg.jul,2026) tested 5 Nov 2026 at BTLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Cagrilintide from Wuhan Wansheng Biotechnology did not meet Finnrick's public standard
Finnrick's public record lists a Cagrilintide sample from Wuhan Wansheng Biotechnology (stated 2 mg, batch September20th) tested 5 Nov 2026 at BTLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Cagrilintide→
- Did not meet standard
Tirzepatide from YH Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from YH Peptide (stated 30 mg, batch Mfg.jul,2026) tested 5 Nov 2026 at BTLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Lunivo Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Lunivo Peptide (stated 5 mg, batch 8530-5) tested 5 Nov 2026 at BTLabs: purity 99.4%, measured 5.2 mg (+4% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Wuhan Newtop Biotech did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Wuhan Newtop Biotech (stated 10 mg, batch Task number #66897 unique key, FU72KAL8GNCT) tested 5 Nov 2026 at PharmLabs: purity 98.53%, measured 10 mg (0% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Wuhan Newtop Biotech did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Wuhan Newtop Biotech (stated 10 mg, batch Task number #66897 unique key, FU72KAL8GNCT) tested 5 Nov 2026 at PharmLabs: purity 98.56%, measured 8.51 mg (-15% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Wuhan Newtop Biotech did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Wuhan Newtop Biotech (stated 10 mg, batch Task number #66897 unique key, FU72KAL8GNCT) tested 5 Nov 2026 at PharmLabs: purity 99.11%, measured 8.12 mg (-19% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Wuhan Newtop Biotech did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Wuhan Newtop Biotech (stated 10 mg, batch Task number #66897 unique key, FU72KAL8GNCT) tested 5 Nov 2026 at PharmLabs: purity 98.88%, measured 8.68 mg (-13% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Daily count
Finnrick published 40 tests on 2026-11-05: 26 met the public standard, 12 did not
On 2026-11-05 Finnrick published 40 independent laboratory tests across its vendor record. 26 met its public Purity Focus standard, 12 did not, 2 could not be classified. Every result is public on Finnrick with the laboratory certificate behind it.
Tue, Nov 3, 2026
- Daily count
Finnrick published 1 test on 2026-11-03: 1 met the public standard, 0 did not
On 2026-11-03 Finnrick published 1 independent laboratory test across its vendor record. 1 met its public Purity Focus standard, 0 did not. Every result is public on Finnrick with the laboratory certificate behind it.
Mon, Nov 2, 2026
- Did not meet standard
Retatrutide from Bfflist AMO did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Bfflist AMO (stated 20 mg, batch July 28, 2026) tested 2 Nov 2026 at Ichor Life Sciences: purity 100%, measured 27.12 mg (+36% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tesamorelin from Peptide Pole Hongkong did not meet Finnrick's public standard
Finnrick's public record lists a Tesamorelin sample from Peptide Pole Hongkong (stated 10 mg, batch PPHK20260907009) tested 2 Nov 2026 at Krause Analytical: purity 99%, measured 8.72 mg (-13% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tesamorelin→
- Did not meet standard
BPC-157 from Norco did not meet Finnrick's public standard
Finnrick's public record lists a BPC-157 sample from Norco (stated 20 mg, batch Lot - Z51 Z12) tested 2 Nov 2026 at PharmLabs: purity 72.18%, measured 17.74 mg (-11% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Tirzepatide from Zhongkechu Peptide Linyi Biotech did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Zhongkechu Peptide Linyi Biotech (stated 30 mg, batch Z51-Z12) tested 2 Nov 2026 at Krause Analytical: purity 72.3%, measured 28.7 mg (-4% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Cagrilintide from Inno Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Cagrilintide sample from Inno Peptides (stated 10 mg, batch SKU: CGL10. #2019010) tested 2 Nov 2026 at Krause Analytical: purity 98.5%, measured 9.96 mg (-0% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Cagrilintide→
- Did not meet standard
Retatrutide from American Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from American Peptides (stated 20 mg, batch June 2026) tested 2 Nov 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Zenith Jove Peptide ZJ did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Zenith Jove Peptide ZJ (stated 5 mg) tested 2 Nov 2026 at Ichor Life Sciences: purity 100%, measured 8.35 mg (+67% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
MOTS-c from Inno Peptides did not meet Finnrick's public standard
Finnrick's public record lists a MOTS-c sample from Inno Peptides (stated 40 mg, batch MFG AUG 26 2026) tested 2 Nov 2026 at Krause Analytical: purity 63.1%, measured 24.2 mg (-40% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
TB-500 from Shanghai ERP peptide Biotechnology did not meet Finnrick's public standard
Finnrick's public record lists a TB-500 sample from Shanghai ERP peptide Biotechnology (stated 5 mg, batch 990008) tested 2 Nov 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Tirzepatide from Hantai Pharma Asia did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Hantai Pharma Asia (stated 40 mg, batch Z51-Z12) tested 2 Nov 2026 at Krause Analytical: purity 75.8%, measured 34.9 mg (-13% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
BPC-157 from HK Peptides did not meet Finnrick's public standard
Finnrick's public record lists a BPC-157 sample from HK Peptides (stated 10 mg) tested 2 Nov 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Ipamorelin from Shanghai Wibson Biotechnology WBS did not meet Finnrick's public standard
Finnrick's public record lists a Ipamorelin sample from Shanghai Wibson Biotechnology WBS (stated 5 mg, batch 990026) tested 2 Nov 2026 at Ichor Life Sciences: purity 95.85%, measured 5.13 mg (+3% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Tirzepatide from Hantai Pharma Asia did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Hantai Pharma Asia (stated 20 mg, batch Z51-Z12) tested 2 Nov 2026 at Krause Analytical: purity 63%, measured 16.9 mg (-16% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
MOTS-c from LP Peptide did not meet Finnrick's public standard
Finnrick's public record lists a MOTS-c sample from LP Peptide (stated 10 mg, batch MS10260912) tested 2 Nov 2026 at Krause Analytical: purity 98.1%, measured 10.1 mg (+1% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Tesamorelin from Simple Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Tesamorelin sample from Simple Peptide (stated 10 mg, batch TESM10-042026-4) tested 2 Nov 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tesamorelin→
- Did not meet standard
Retatrutide from Unicorn Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Unicorn Peptide (stated 20 mg, batch RT-26072) tested 2 Nov 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Wuhan Wansheng Biotechnology did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Wuhan Wansheng Biotechnology (stated 30 mg, batch 20260715) tested 2 Nov 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tesamorelin from Tianjin Ruiwang New Material Technology Co did not meet Finnrick's public standard
Finnrick's public record lists a Tesamorelin sample from Tianjin Ruiwang New Material Technology Co (stated 10 mg, batch July 25,2026) tested 2 Nov 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tesamorelin→
- Did not meet standard
Ipamorelin from Shanghai Wibson Biotechnology WBS did not meet Finnrick's public standard
Finnrick's public record lists a Ipamorelin sample from Shanghai Wibson Biotechnology WBS (stated 5 mg, batch 990026) tested 2 Nov 2026 at Ichor Life Sciences: purity 95.39%, measured 5.17 mg (+3% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
MOTS-c from Inno Peptides did not meet Finnrick's public standard
Finnrick's public record lists a MOTS-c sample from Inno Peptides (stated 10 mg, batch MFG AUG 24 2026) tested 2 Nov 2026 at Krause Analytical: purity 98.1%, measured 11.9 mg (+19% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
BPC-157 from Peptide Pole Hongkong did not meet Finnrick's public standard
Finnrick's public record lists a BPC-157 sample from Peptide Pole Hongkong (stated 20 mg, batch BB20) tested 2 Nov 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Tirzepatide from Unicorn Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Unicorn Peptide (stated 30 mg, batch TR-26084) tested 2 Nov 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
MOTS-c from Reta-Peptide did not meet Finnrick's public standard
Finnrick's public record lists a MOTS-c sample from Reta-Peptide (stated 10 mg, batch 09/27/2016) tested 2 Nov 2026 at Krause Analytical: purity 98.5%, measured 11.1 mg (+11% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Tirzepatide from Shanghai ERP peptide Biotechnology did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Shanghai ERP peptide Biotechnology (stated 30 mg, batch TR30 Orange Cap) tested 2 Nov 2026 at Ichor Life Sciences: purity 97.88%, measured 31.46 mg (+5% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Group Buy Kits GBK did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Group Buy Kits GBK (stated 10 mg, batch 00088-3-0726-RT10) tested 2 Nov 2026 at Krause Analytical: purity 99.1%, measured 8.42 mg (-16% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
TB-500 from Mai Peptide did not meet Finnrick's public standard
Finnrick's public record lists a TB-500 sample from Mai Peptide (stated 10 mg, batch May 14, 2026) tested 2 Nov 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from Guangdong Tyran Technology Group did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Guangdong Tyran Technology Group (stated 30 mg) tested 2 Nov 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from QH Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from QH Peptide (stated 30 mg, batch TIR003) tested 2 Nov 2026 at Ichor Life Sciences: purity 97.55%, measured 30.43 mg (+1% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Simple Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Simple Peptide (stated 20 mg, batch 2001020) tested 2 Nov 2026 at Ichor Life Sciences: purity 88.89%, measured 23.91 mg (+20% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from Zhongkechu Peptide Linyi Biotech did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Zhongkechu Peptide Linyi Biotech (stated 20 mg, batch Z51Z12) tested 2 Nov 2026 at Krause Analytical: purity 63.9%, measured 18.7 mg (-7% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Nova Bio Labs did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Nova Bio Labs (stated 20 mg, batch Exp sep2028, RT20) tested 2 Nov 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from A-Orange did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from A-Orange (stated 15 mg, batch July 2026) tested 2 Nov 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
TB-500 from Kerui Peptide HongKong did not meet Finnrick's public standard
Finnrick's public record lists a TB-500 sample from Kerui Peptide HongKong (stated 10 mg) tested 2 Nov 2026 at Krause Analytical: purity 99.2%, measured 9.41 mg (-6% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
HGH from Qingdao Sigma Chemical QSC did not meet Finnrick's public standard
Finnrick's public record lists a HGH sample from Qingdao Sigma Chemical QSC (stated 10 IU, batch no lot number. Nothing printed on box or vial) tested 2 Nov 2026 at Krause Analytical: purity 84%, measured 17.1 IU (+71% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from Kerui Peptide HongKong did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Kerui Peptide HongKong (stated 15 mg) tested 2 Nov 2026 at Krause Analytical: purity 99.4%, measured 10.9 mg (-27% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Guangdong Tyran Technology Group did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Guangdong Tyran Technology Group (stated 20 mg, batch Z51-Z12) tested 2 Nov 2026 at PharmLabs: purity 70.84%, measured 20.69 mg (+3% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Nova Bio Labs did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Nova Bio Labs (stated 10 mg, batch Mfg. Mar 2026) tested 2 Nov 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from QYA BIO China Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from QYA BIO China Peptides (stated 30 mg, batch 06/01/202) tested 2 Nov 2026 at PharmLabs: purity 99.99%, measured 18.55 mg (-38% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Glutathione from Heman Peptide HM did not meet Finnrick's public standard
Finnrick's public record lists a Glutathione sample from Heman Peptide HM (stated 600 mg) tested 2 Nov 2026 at Krause Analytical: purity 90.5%, measured 648 mg (+8% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Glutathione→
- Did not meet standard
Tirzepatide from Xingtai Jiachuang Technology did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Xingtai Jiachuang Technology (stated 30 mg, batch WEIZH152701 260527) tested 2 Nov 2026 at Ichor Life Sciences: purity 81.12%, measured 29.79 mg (-1% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Daily count
Finnrick published 82 tests on 2026-11-02: 41 met the public standard, 40 did not
On 2026-11-02 Finnrick published 82 independent laboratory tests across its vendor record. 41 met its public Purity Focus standard, 40 did not, 1 could not be classified. Every result is public on Finnrick with the laboratory certificate behind it.
Fri, Oct 30, 2026
- Did not meet standard
Tirzepatide from Uther did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Uther (stated 60 mg, batch TR60-1234) tested 30 Oct 2026 at Harrens Lab: purity 58.8%, measured 35.25 mg (-41% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from Mokemei Zhengzhou Biotechnology MKM did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Mokemei Zhengzhou Biotechnology MKM (stated 40 mg, batch Jun 23 2026) tested 30 Oct 2026 at Harrens Lab: purity 84.4%, measured 33.77 mg (-16% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
GHK-Cu from Lumira did not meet Finnrick's public standard
Finnrick's public record lists a GHK-Cu sample from Lumira (stated 50 mg) tested 30 Oct 2026 at Harrens Lab: purity 50.6%, measured 26.28 mg (-47% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Tirzepatide from Lumira did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Lumira (stated 30 mg, batch PPA-WL-2S10-P00901) tested 30 Oct 2026 at Harrens Lab: purity 54.36%, measured 16.31 mg (-46% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from Wuhan Wansheng Biotechnology did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Wuhan Wansheng Biotechnology (stated 10 mg, batch 258007) tested 30 Oct 2026 at Harrens Lab: purity 94.4%, measured 9.44 mg (-6% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Daily count
Finnrick published 15 tests on 2026-10-30: 10 met the public standard, 5 did not
On 2026-10-30 Finnrick published 15 independent laboratory tests across its vendor record. 10 met its public Purity Focus standard, 5 did not. Every result is public on Finnrick with the laboratory certificate behind it.
Thu, Oct 29, 2026
- Did not meet standard
Semaglutide from Mai Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Semaglutide sample from Mai Peptide (stated 5 mg, batch July 12, 2026) tested 29 Oct 2026 at BTLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Semaglutide→
- Did not meet standard
Tesamorelin from SPB did not meet Finnrick's public standard
Finnrick's public record lists a Tesamorelin sample from SPB (stated 10 mg, batch None) tested 29 Oct 2026 at BTLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tesamorelin→
- Daily count
Finnrick published 52 tests on 2026-10-29: 12 met the public standard, 2 did not
On 2026-10-29 Finnrick published 52 independent laboratory tests across its vendor record. 12 met its public Purity Focus standard, 2 did not, 38 could not be classified. Every result is public on Finnrick with the laboratory certificate behind it.
Wed, Oct 28, 2026
- Did not meet standard
Retatrutide from XTP did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from XTP (stated 30 mg, batch XTP-R30-003) tested 28 Oct 2026 at PharmLabs: purity 85.41%, measured 27.67 mg (-8% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Novabio Research (stated 10 mg, batch 0010a01) tested 28 Oct 2026 at PharmLabs: purity 99.99%, measured 4.97 mg (-50% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 30 mg, batch Sep 2028) tested 28 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Shanghai JinBei Chemical Technology did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Shanghai JinBei Chemical Technology (stated 20 mg, batch Aug. 20, 2026) tested 28 Oct 2026 at PharmLabs: purity 99.99%, measured 10.02 mg (-50% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 20 mg, batch Sep 2028) tested 28 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 30 mg, batch No lot number) tested 28 Oct 2026 at Krause Analytical: purity 99.9%, measured 4.37 mg (-85% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Kerui Peptide HongKong did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Kerui Peptide HongKong (stated 20 mg, batch Pb-2026-ret-8+02) tested 28 Oct 2026 at PharmLabs: purity 99.99%, measured 8.44 mg (-58% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Novabio Research (stated 40 mg, batch Sep 2028) tested 28 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Novabio Research (stated 20 mg, batch Sep 2028) tested 28 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Golden Age Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Golden Age Peptide (stated 20 mg, batch 26080501) tested 28 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Lisa Biopeptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Lisa Biopeptide (stated 20 mg, batch RT20-203405-R) tested 28 Oct 2026 at PharmLabs: purity 99.99%, measured 33.56 mg (+68% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from BeiBangAn did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from BeiBangAn (stated 40 mg, batch 258041) tested 28 Oct 2026 at PharmLabs: purity 99.99%, measured 12.84 mg (-68% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Daily count
Finnrick published 18 tests on 2026-10-28: 3 met the public standard, 12 did not
On 2026-10-28 Finnrick published 18 independent laboratory tests across its vendor record. 3 met its public Purity Focus standard, 12 did not, 3 could not be classified. Every result is public on Finnrick with the laboratory certificate behind it.
Tue, Oct 27, 2026
- Did not meet standard
Retatrutide from Cellupep did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Cellupep (stated 20 mg, batch July 10th 2026) tested 27 Oct 2026 at PharmLabs: purity 97.79%, measured 18.91 mg (-5% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Daily count
Finnrick published 21 tests on 2026-10-27: 20 met the public standard, 1 did not
On 2026-10-27 Finnrick published 21 independent laboratory tests across its vendor record. 20 met its public Purity Focus standard, 1 did not. Every result is public on Finnrick with the laboratory certificate behind it.
Fri, Oct 23, 2026
- Did not meet standard
Tirzepatide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Novabio Research (stated 10 mg) tested 23 Oct 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
HGH from Qingdao Sigma Chemical QSC did not meet Finnrick's public standard
Finnrick's public record lists a HGH sample from Qingdao Sigma Chemical QSC (stated 15 IU, batch HQD) tested 23 Oct 2026 at Krause Analytical: purity 87.9%, measured 17.1 IU (+14% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Tirzepatide from MGC Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from MGC Peptides (stated 30 mg, batch Jun 04, 2026) tested 23 Oct 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Tianjin Ruiwang New Material Technology Co did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Tianjin Ruiwang New Material Technology Co (stated 20 mg, batch July ,25 2026) tested 23 Oct 2026 at Krause Analytical: purity 64.5%, measured 23.6 mg (+18% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from Marvel Pep did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Marvel Pep (stated 30 mg, batch 260135) tested 23 Oct 2026 at Krause Analytical: purity 93%, measured 28.6 mg (-5% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
CJC-1295 from Lumira did not meet Finnrick's public standard
Finnrick's public record lists a CJC-1295 sample from Lumira (stated 5 mg, batch 000274) tested 23 Oct 2026 at BTLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Tirzepatide from Shanghai ERP peptide Biotechnology did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Shanghai ERP peptide Biotechnology (stated 60 mg, batch Red Cap) tested 23 Oct 2026 at Krause Analytical: purity 99.9%, measured 108 mg (+80% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
NAD+ from LP Peptide did not meet Finnrick's public standard
Finnrick's public record lists a NAD+ sample from LP Peptide (stated 1000 mg, batch NJ10260529) tested 23 Oct 2026 at Krause Analytical: purity 86%, measured 888 mg (-11% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Daily count
Finnrick published 38 tests on 2026-10-23: 30 met the public standard, 8 did not
On 2026-10-23 Finnrick published 38 independent laboratory tests across its vendor record. 30 met its public Purity Focus standard, 8 did not. Every result is public on Finnrick with the laboratory certificate behind it.
Wed, Oct 21, 2026
- Did not meet standard
Retatrutide from Purely Pep Lab did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Purely Pep Lab (stated 10 mg, batch 2026.8.22) tested 21 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from ChemExpress did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from ChemExpress (stated 20 mg, batch AUGUST 25,2026) tested 21 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 30 mg, batch No Batch Number or Lot Number) tested 21 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
BPC-157 from Norco did not meet Finnrick's public standard
Finnrick's public record lists a BPC-157 sample from Norco (stated 10 mg, batch Z51Z1) tested 21 Oct 2026 at PharmLabs: purity 56.66%, measured 9.79 mg (-2% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from A-Orange did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from A-Orange (stated 10 mg, batch July 2026) tested 21 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Inno Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Inno Peptides (stated 10 mg, batch 2001010) tested 21 Oct 2026 at PharmLabs: purity 97.25%, measured 8.4 mg (-16% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 10 mg, batch march 2026) tested 21 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 20 mg, batch Mfg mar 2026) tested 21 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Daily count
Finnrick published 8 tests on 2026-10-21: 0 met the public standard, 8 did not
On 2026-10-21 Finnrick published 8 independent laboratory tests across its vendor record. 0 met its public Purity Focus standard, 8 did not. Every result is public on Finnrick with the laboratory certificate behind it.
Tue, Oct 20, 2026
- Did not meet standard
Retatrutide from Zen Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Zen Peptides (stated 10 mg, batch N/A) tested 20 Oct 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from Andy Peps Studio did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Andy Peps Studio (stated 20 mg, batch TWQY MFD 2026/6/12 exp 2028/6/11) tested 20 Oct 2026 at Ichor Life Sciences: purity 100%, measured 32 mg (+60% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Wanshun Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Wanshun Peptide (stated 20 mg, batch Lot 15, 8/9/26) tested 20 Oct 2026 at Ichor Life Sciences: purity 100%, measured 35.55 mg (+78% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Xingruida XDR did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Xingruida XDR (stated 30 mg, batch Mfg: Jul. 2026) tested 20 Oct 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
BPC-157 from Kerui Peptide HongKong did not meet Finnrick's public standard
Finnrick's public record lists a BPC-157 sample from Kerui Peptide HongKong (stated 10 mg) tested 20 Oct 2026 at Ichor Life Sciences: purity 99.29%, measured 11.04 mg (+10% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from Boruimei did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Boruimei (stated 30 mg, batch 08/15/2026) tested 20 Oct 2026 at Ichor Life Sciences: purity 100%, measured 42.84 mg (+43% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Wanshun Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Wanshun Peptide (stated 10 mg, batch Lot 6, 8/11/26) tested 20 Oct 2026 at Ichor Life Sciences: purity 100%, measured 19.24 mg (+92% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
BPC-157 from Lumira did not meet Finnrick's public standard
Finnrick's public record lists a BPC-157 sample from Lumira (stated 10 mg, batch WL-BC10-000239) tested 20 Oct 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from Limitless Life Nootropics did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Limitless Life Nootropics (stated 8 mg, batch 1297) tested 20 Oct 2026 at BTLabs: purity 99.9%, measured 11.7 mg (+46% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Cagrilintide from Shanghai Wibson Biotechnology WBS did not meet Finnrick's public standard
Finnrick's public record lists a Cagrilintide sample from Shanghai Wibson Biotechnology WBS (stated 5 mg, batch 990001) tested 20 Oct 2026 at BTLabs: purity 99.4%, measured 5.1 mg (+2% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Cagrilintide→
- Did not meet standard
Tirzepatide from Guangzhou Aoyu did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Guangzhou Aoyu (stated 30 mg, batch TR30-041326-Jessica) tested 20 Oct 2026 at BTLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from Guangzhou Aoyu did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Guangzhou Aoyu (stated 60 mg, batch TR60-041326-Jessica) tested 20 Oct 2026 at BTLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from Guangzhou Aoyu did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Guangzhou Aoyu (stated 10 mg, batch TR10-050226-Cora) tested 20 Oct 2026 at BTLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Daily count
Finnrick published 6 tests on 2026-10-20: 5 met the public standard, 1 did not
On 2026-10-20 Finnrick published 6 independent laboratory tests across its vendor record. 5 met its public Purity Focus standard, 1 did not. Every result is public on Finnrick with the laboratory certificate behind it.
Fri, Oct 16, 2026
- Did not meet standard
Tirzepatide from SP Research did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from SP Research (stated 30 mg) tested 16 Oct 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Pure Peptide Labs did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Pure Peptide Labs (stated 30 mg, batch July 28,2026) tested 16 Oct 2026 at Harrens Lab: purity 33.7%, measured 10.1 mg (-66% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from Fashion Pep did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Fashion Pep (stated 30 mg, batch Mar 30, 2026) tested 16 Oct 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from Jinan Elitepeptide Chemical JEC JCE did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Jinan Elitepeptide Chemical JEC JCE (stated 30 mg, batch MG622-622004) tested 16 Oct 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Retalux did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Retalux (stated 20 mg, batch Ppa-rl-rt20-r00223) tested 16 Oct 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Shenzhen Jiechuang Trading did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Shenzhen Jiechuang Trading (stated 20 mg, batch PED26082201) tested 16 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Daily count
Finnrick published 15 tests on 2026-10-16: 9 met the public standard, 6 did not
On 2026-10-16 Finnrick published 15 independent laboratory tests across its vendor record. 9 met its public Purity Focus standard, 6 did not. Every result is public on Finnrick with the laboratory certificate behind it.
Thu, Oct 15, 2026
- Did not meet standard
Retatrutide from Guangzhou Aoyu did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Guangzhou Aoyu (stated 10 mg, batch RT10-041326-Jessica) tested 15 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Golden Age Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Golden Age Peptide (stated 120 mg, batch Batch: 26082903. MFD: 260901. EXP: 280902) tested 15 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Hong Kong Meiliduo Technology Limited did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Hong Kong Meiliduo Technology Limited (stated 20 mg, batch Mfg:6/23/26) tested 15 Oct 2026 at PharmLabs: purity 99.99%, measured 6.97 mg (-65% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 10 mg, batch COA) tested 15 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 20 mg, batch Lot # 001) tested 15 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 30 mg, batch 2608130282) tested 15 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Baohua Dongnuo Biotechnology BHD did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Baohua Dongnuo Biotechnology BHD (stated 20 mg, batch 2026.6.23) tested 15 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from AoTai Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from AoTai Peptide (stated 30 mg, batch Aug 2026) tested 15 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 20 mg, batch COA) tested 15 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 20 mg, batch Lot # 001) tested 15 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
CJC-1295 from Liberty Peptides did not meet Finnrick's public standard
Finnrick's public record lists a CJC-1295 sample from Liberty Peptides (stated 10 mg, batch LPUS029001) tested 15 Oct 2026 at Krause Analytical: purity 90.8%, measured 8.73 mg (-13% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Daily count
Finnrick published 13 tests on 2026-10-15: 1 met the public standard, 11 did not
On 2026-10-15 Finnrick published 13 independent laboratory tests across its vendor record. 1 met its public Purity Focus standard, 11 did not, 1 could not be classified. Every result is public on Finnrick with the laboratory certificate behind it.
Wed, Oct 14, 2026
- Did not meet standard
Retatrutide from ZePeptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from ZePeptide (stated 10 mg, batch 2026.9.1) tested 14 Oct 2026 at BTLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
BPC-157 from ZePeptide did not meet Finnrick's public standard
Finnrick's public record lists a BPC-157 sample from ZePeptide (stated 10 mg, batch 2026.9.1) tested 14 Oct 2026 at BTLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Tirzepatide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Novabio Research (stated 10 mg, batch Lot # 0010a01) tested 14 Oct 2026 at PharmLabs: purity 99.99%, measured 5.07 mg (-49% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Daily count
Finnrick published 27 tests on 2026-10-14: 24 met the public standard, 3 did not
On 2026-10-14 Finnrick published 27 independent laboratory tests across its vendor record. 24 met its public Purity Focus standard, 3 did not. Every result is public on Finnrick with the laboratory certificate behind it.
Tue, Oct 13, 2026
- Did not meet standard
Tesamorelin from Inno Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Tesamorelin sample from Inno Peptides (stated 10 mg, batch 26427157) tested 13 Oct 2026 at Krause Analytical: purity 98.8%, measured 8.4 mg (-16% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tesamorelin→
- Did not meet standard
Retatrutide from Verified Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Verified Peptides (stated 10 mg, batch VP200715A) tested 13 Oct 2026 at Krause Analytical: purity 99.4%, measured 8.99 mg (-10% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Ipamorelin from Reta-Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Ipamorelin sample from Reta-Peptide (stated 5 mg, batch 4/2/2026) tested 13 Oct 2026 at Krause Analytical: purity 99.3%, measured 4.97 mg (-1% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Tesamorelin from Shanghai ERP peptide Biotechnology did not meet Finnrick's public standard
Finnrick's public record lists a Tesamorelin sample from Shanghai ERP peptide Biotechnology (stated 10 mg, batch 990025) tested 13 Oct 2026 at Krause Analytical: purity 99.2%, measured 8.1 mg (-19% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tesamorelin→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 20 mg, batch Nova-1685801) tested 13 Oct 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Ipamorelin from Shanghai ERP peptide Biotechnology did not meet Finnrick's public standard
Finnrick's public record lists a Ipamorelin sample from Shanghai ERP peptide Biotechnology (stated 10 mg, batch 990027) tested 13 Oct 2026 at Ichor Life Sciences: purity 99.16%, measured 10.161 mg (+2% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from Lunivo Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Lunivo Peptide (stated 20 mg, batch 8350-7) tested 13 Oct 2026 at Krause Analytical: purity 99.3%, measured 17.4 mg (-13% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Yiwu Aozuo Trading Co did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Yiwu Aozuo Trading Co (stated 20 mg, batch NA) tested 13 Oct 2026 at Krause Analytical: purity 99.2%, measured 18 mg (-10% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Ipamorelin from Shanghai ERP peptide Biotechnology did not meet Finnrick's public standard
Finnrick's public record lists a Ipamorelin sample from Shanghai ERP peptide Biotechnology (stated 10 mg, batch 990027) tested 13 Oct 2026 at Krause Analytical: purity 99.2%, measured 10.8 mg (+8% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from HKPep did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from HKPep (stated 10 mg) tested 13 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Daily count
Finnrick published 34 tests on 2026-10-13: 24 met the public standard, 10 did not
On 2026-10-13 Finnrick published 34 independent laboratory tests across its vendor record. 24 met its public Purity Focus standard, 10 did not. Every result is public on Finnrick with the laboratory certificate behind it.
Mon, Oct 12, 2026
- Did not meet standard
Retatrutide from Amino Asylum did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Amino Asylum (stated 10 mg, batch RT10) tested 12 Oct 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Noble Dragons did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Noble Dragons (stated 20 mg, batch RT20-260709) tested 12 Oct 2026 at Krause Analytical: purity 98.1%, measured 18.8 mg (-6% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from Homopeptide did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Homopeptide (stated 20 mg, batch 8/5/2026) tested 12 Oct 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
NAD+ from Lipeptides did not meet Finnrick's public standard
Finnrick's public record lists a NAD+ sample from Lipeptides (stated 100 mg) tested 12 Oct 2026 at Krause Analytical: purity 98.1%, measured 110 mg (+10% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
BPC-157 from Pure Peptide Labs did not meet Finnrick's public standard
Finnrick's public record lists a BPC-157 sample from Pure Peptide Labs (stated 20 mg, batch ppl8312026) tested 12 Oct 2026 at Krause Analytical: purity 99.9%, measured 7.4 mg (-63% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
MOTS-c from Reta-Peptide did not meet Finnrick's public standard
Finnrick's public record lists a MOTS-c sample from Reta-Peptide (stated 40 mg, batch 9/2/2026) tested 12 Oct 2026 at Krause Analytical: purity 98.4%, measured 39.9 mg (-0% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from YuanSense Tech did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from YuanSense Tech (stated 10 mg, batch August 03 2026) tested 12 Oct 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tesamorelin from NovaPeptide did not meet Finnrick's public standard
Finnrick's public record lists a Tesamorelin sample from NovaPeptide (stated 10 mg, batch 01260820310L) tested 12 Oct 2026 at Krause Analytical: purity 98.9%, measured 11.2 mg (+12% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tesamorelin→
- Did not meet standard
Tirzepatide from Sediao Chemical did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Sediao Chemical (stated 40 mg) tested 12 Oct 2026 at BTLabs: purity 99.9%, measured 20.4 mg (-49% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from Sediao Chemical did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Sediao Chemical (stated 50 mg) tested 12 Oct 2026 at BTLabs: purity 99.9%, measured 31.7 mg (-37% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from ZLZ Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from ZLZ Peptide (stated 20 mg, batch RT20-ZLZ02) tested 12 Oct 2026 at Krause Analytical: purity 98.9%, measured 18.2 mg (-9% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from Sediao Chemical did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Sediao Chemical (stated 30 mg) tested 12 Oct 2026 at BTLabs: purity 99.9%, measured 10.3 mg (-66% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Daily count
Finnrick published 60 tests on 2026-10-12: 42 met the public standard, 9 did not
On 2026-10-12 Finnrick published 60 independent laboratory tests across its vendor record. 42 met its public Purity Focus standard, 9 did not, 9 could not be classified. Every result is public on Finnrick with the laboratory certificate behind it.
Fri, Oct 9, 2026
- Did not meet standard
Retatrutide from Changsha Caoquan Technology did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Changsha Caoquan Technology (stated 15 mg, batch RETA-4287-589) tested 9 Oct 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Huaian Hanyou Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Huaian Hanyou Peptide (stated 10 mg, batch Y4SPPSB) tested 9 Oct 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Henan Sahe Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Henan Sahe Peptide (stated 30 mg, batch Fifteen.7.2026) tested 9 Oct 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from LP Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from LP Peptide (stated 5 mg, batch PED26050201) tested 9 Oct 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Daily count
Finnrick published 24 tests on 2026-10-09: 20 met the public standard, 4 did not
On 2026-10-09 Finnrick published 24 independent laboratory tests across its vendor record. 20 met its public Purity Focus standard, 4 did not. Every result is public on Finnrick with the laboratory certificate behind it.
Thu, Oct 8, 2026
- Did not meet standard
Retatrutide from Pure Peptide Labs did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Pure Peptide Labs (stated 20 mg, batch ppl7302026) tested 8 Oct 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Shenzhen Qiyoukai Trading did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Shenzhen Qiyoukai Trading (stated 10 mg) tested 8 Oct 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 30 mg, batch Mar 2026) tested 8 Oct 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Guangzhou yunyu trading did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Guangzhou yunyu trading (stated 10 mg) tested 8 Oct 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Cagrilintide from EHZ Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Cagrilintide sample from EHZ Peptides (stated 5 mg, batch CGL50529) tested 8 Oct 2026 at Krause Analytical: purity 99.9%, measured 2.81 mg (-44% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Cagrilintide→
- Did not meet standard
Tirzepatide from LP Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from LP Peptide (stated 30 mg, batch 111343) tested 8 Oct 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from LP Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from LP Peptide (stated 30 mg, batch 26082301) tested 8 Oct 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Daily count
Finnrick published 13 tests on 2026-10-08: 10 met the public standard, 3 did not
On 2026-10-08 Finnrick published 13 independent laboratory tests across its vendor record. 10 met its public Purity Focus standard, 3 did not. Every result is public on Finnrick with the laboratory certificate behind it.
Wed, Oct 7, 2026
- Did not meet standard
Tesamorelin from Zhengzhou Lan Yun Cosmetic Trading did not meet Finnrick's public standard
Finnrick's public record lists a Tesamorelin sample from Zhengzhou Lan Yun Cosmetic Trading (stated 10 mg, batch May 12, 2026) tested 7 Oct 2026 at Ichor Life Sciences: purity 98.57%, measured 11.5785 mg (+16% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tesamorelin→
- Did not meet standard
Tesamorelin from NovaPeptide did not meet Finnrick's public standard
Finnrick's public record lists a Tesamorelin sample from NovaPeptide (stated 5 mg, batch 0126090935L) tested 7 Oct 2026 at Ichor Life Sciences: purity 98.5%, measured 5.38948 mg (+8% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tesamorelin→
- Daily count
Finnrick published 2 tests on 2026-10-07: 0 met the public standard, 2 did not
On 2026-10-07 Finnrick published 2 independent laboratory tests across its vendor record. 0 met its public Purity Focus standard, 2 did not. Every result is public on Finnrick with the laboratory certificate behind it.
Tue, Oct 6, 2026
- Did not meet standard
Tirzepatide from Orbitrex Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Orbitrex Peptides (stated 30 mg, batch 2g30726) tested 6 Oct 2026 at Harrens Lab: purity 55.9%, measured 16.78 mg (-44% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from Allen Biotechnology Co ABC did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Allen Biotechnology Co ABC (stated 30 mg, batch 3/15/26) tested 6 Oct 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from Guangzhou Aoyu did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Guangzhou Aoyu (stated 30 mg, batch May10rt10) tested 6 Oct 2026 at Harrens Lab: purity 99.9%, measured 12.99 mg (-57% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 20 mg, batch 03/2026) tested 6 Oct 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
TB-500 from Lumira did not meet Finnrick's public standard
Finnrick's public record lists a TB-500 sample from Lumira (stated 10 mg, batch PPA-WL-TB10-P00714) tested 6 Oct 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Semaglutide from INDR Labs did not meet Finnrick's public standard
Finnrick's public record lists a Semaglutide sample from INDR Labs (stated 10 mg, batch 04/21/26) tested 6 Oct 2026 at BTLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Semaglutide→
- Did not meet standard
Retatrutide from Tianjin TaiHeng Trading did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Tianjin TaiHeng Trading (stated 20 mg, batch May 16, 2026) tested 6 Oct 2026 at Ichor Life Sciences: purity 100%, measured 27.7276 mg (+39% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 30 mg, batch Mar 2026) tested 6 Oct 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Novabio Research (stated 50 mg, batch mar. 2026) tested 6 Oct 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Guangzhou Aoyu did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Guangzhou Aoyu (stated 10 mg, batch 002) tested 6 Oct 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
GHK-Cu from SubQ Society did not meet Finnrick's public standard
Finnrick's public record lists a GHK-Cu sample from SubQ Society (stated 100 mg, batch 04202026) tested 6 Oct 2026 at Ichor Life Sciences: purity 98.81%, measured 113.414 mg (+13% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
GHK-Cu from Bulk Peptide Wholesale did not meet Finnrick's public standard
Finnrick's public record lists a GHK-Cu sample from Bulk Peptide Wholesale (stated 100 mg) tested 6 Oct 2026 at BTLabs: purity 77.3%, measured 66.2 mg (-34% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from Tianjin Ruiwang New Material Technology Co did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Tianjin Ruiwang New Material Technology Co (stated 30 mg, batch July 25,2026) tested 6 Oct 2026 at BTLabs: purity 11.2%, measured 30.5 mg (+2% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Ipamorelin from Heman Peptide HM did not meet Finnrick's public standard
Finnrick's public record lists a Ipamorelin sample from Heman Peptide HM (stated 10 mg, batch Jul 27 2026) tested 6 Oct 2026 at Ichor Life Sciences: purity 95.34%, measured 11.371 mg (+14% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Cagrilintide from Henan Sahe Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Cagrilintide sample from Henan Sahe Peptide (stated 10 mg, batch 05-10-23) tested 6 Oct 2026 at BTLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Cagrilintide→
- Did not meet standard
Retatrutide from EHZ Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from EHZ Peptides (stated 30 mg, batch 8/15/2026) tested 6 Oct 2026 at Ichor Life Sciences: purity 100%, measured 44.6564 mg (+49% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
BPC-157 from Lumira did not meet Finnrick's public standard
Finnrick's public record lists a BPC-157 sample from Lumira (stated 10 mg, batch PPA-WL-BC10-P00704) tested 6 Oct 2026 at Ichor Life Sciences: purity 97.78%, measured 10.5852 mg (+6% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Semaglutide from INDR Labs did not meet Finnrick's public standard
Finnrick's public record lists a Semaglutide sample from INDR Labs (stated 10 mg, batch 04/21/26) tested 6 Oct 2026 at BTLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Semaglutide→
- Did not meet standard
Retatrutide from Hengan Peptide Factory did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Hengan Peptide Factory (stated 30 mg, batch 2026/09) tested 6 Oct 2026 at Ichor Life Sciences: purity 100%, measured 42.8034 mg (+43% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
GHK-Cu from Orbitrex Peptides did not meet Finnrick's public standard
Finnrick's public record lists a GHK-Cu sample from Orbitrex Peptides (stated 50 mg, batch GHKCU50726IS) tested 6 Oct 2026 at Ichor Life Sciences: purity 100%, measured 68.8951 mg (+38% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from Guangzhou yunyu trading did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Guangzhou yunyu trading (stated 30 mg, batch 568420260605) tested 6 Oct 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from SubQ Society did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from SubQ Society (stated 20 mg, batch 04202028) tested 6 Oct 2026 at Ichor Life Sciences: purity 100%, measured 29.2028 mg (+46% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
NAD+ from ZLZ Peptide did not meet Finnrick's public standard
Finnrick's public record lists a NAD+ sample from ZLZ Peptide (stated 500 mg, batch NJ500-ZLZ02) tested 6 Oct 2026 at BTLabs: purity 99.9%, measured 1567.2 mg (+213% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from Zenith Jove Peptide ZJ did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Zenith Jove Peptide ZJ (stated 30 mg, batch ZJ 2481) tested 6 Oct 2026 at Ichor Life Sciences: purity 100%, measured 42.4541 mg (+42% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 10 mg, batch Mar 2026) tested 6 Oct 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
BPC-157 from Yiwu Aozuo Trading Co did not meet Finnrick's public standard
Finnrick's public record lists a BPC-157 sample from Yiwu Aozuo Trading Co (stated 5 mg, batch June 6 2026) tested 6 Oct 2026 at Ichor Life Sciences: purity 97.69%, measured 5.16597 mg (+3% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Daily count
Finnrick published 69 tests on 2026-10-06: 47 met the public standard, 22 did not
On 2026-10-06 Finnrick published 69 independent laboratory tests across its vendor record. 47 met its public Purity Focus standard, 22 did not. Every result is public on Finnrick with the laboratory certificate behind it.
Mon, Oct 5, 2026
- Did not meet standard
Retatrutide from Guangdong Tyran Technology Group did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Guangdong Tyran Technology Group (stated 50 mg, batch 19/8/2026) tested 5 Oct 2026 at Harrens Lab: purity 35.4%, measured 17.69 mg (-65% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 20 mg, batch 03-2028 exp) tested 5 Oct 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Tirz Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Tirz Peptide (stated 10 mg, batch MGD) tested 5 Oct 2026 at Harrens Lab: purity 6.9%, measured 0.69 mg (-93% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from ZePeptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from ZePeptide (stated 30 mg, batch 70413005609) tested 5 Oct 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Peptide Healths did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Peptide Healths (stated 30 mg, batch March 2026) tested 5 Oct 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Wellness Research Supply did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Wellness Research Supply (stated 30 mg, batch 2WJWRG) tested 5 Oct 2026 at Krause Analytical: purity 99.4%, measured 28.9 mg (-4% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Daily count
Finnrick published 18 tests on 2026-10-05: 11 met the public standard, 6 did not
On 2026-10-05 Finnrick published 18 independent laboratory tests across its vendor record. 11 met its public Purity Focus standard, 6 did not, 1 could not be classified. Every result is public on Finnrick with the laboratory certificate behind it.
Sat, Oct 3, 2026
- Daily count
Finnrick published 5 tests on 2026-10-03: 5 met the public standard, 0 did not
On 2026-10-03 Finnrick published 5 independent laboratory tests across its vendor record. 5 met its public Purity Focus standard, 0 did not. Every result is public on Finnrick with the laboratory certificate behind it.
Thu, Oct 1, 2026
- Did not meet standard
Semaglutide from ZLZ Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Semaglutide sample from ZLZ Peptide (stated 15 mg, batch 2026-03-05) tested 1 Oct 2026 at Krause Analytical: purity 98.9%, measured 17.2 mg (+15% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Semaglutide→
- Did not meet standard
BPC-157 from Kerui Peptide HongKong did not meet Finnrick's public standard
Finnrick's public record lists a BPC-157 sample from Kerui Peptide HongKong (stated 5 mg, batch 20260903BP) tested 1 Oct 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
5-Amino-1MQ from Shanghai ERP peptide Biotechnology did not meet Finnrick's public standard
Finnrick's public record lists a 5-Amino-1MQ sample from Shanghai ERP peptide Biotechnology (stated 50 mg, batch 990062) tested 1 Oct 2026 at Krause Analytical: purity 98.9%, measured 49.7 mg (-1% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for 5-Amino-1MQ→
- Did not meet standard
GHK-Cu from PeptiAtlas did not meet Finnrick's public standard
Finnrick's public record lists a GHK-Cu sample from PeptiAtlas (stated 50 mg, batch April 3 2026) tested 1 Oct 2026 at Harrens Lab: purity 10%, measured 5 mg (-90% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from Purely Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Purely Peptides (stated 30 mg, batch RET-20260811-01) tested 1 Oct 2026 at Krause Analytical: purity 99.3%, measured 28.7 mg (-4% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
NAD+ from LP Peptide did not meet Finnrick's public standard
Finnrick's public record lists a NAD+ sample from LP Peptide (stated 1000 mg, batch NJ1026060201) tested 1 Oct 2026 at Krause Analytical: purity 94.3%, measured 787 mg (-21% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Tirzepatide from Mammoth Biotech did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Mammoth Biotech (stated 15 mg) tested 1 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
GHK-Cu from SRY Labs did not meet Finnrick's public standard
Finnrick's public record lists a GHK-Cu sample from SRY Labs (stated 50 mg, batch GHK-CU50) tested 1 Oct 2026 at Krause Analytical: purity 99.3%, measured 48 mg (-4% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Tirzepatide from Mammoth Biotech did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Mammoth Biotech (stated 30 mg) tested 1 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from LP Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from LP Peptide (stated 30 mg, batch TR30-LP, PED26050201) tested 1 Oct 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Xianhong Tong XHT Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Xianhong Tong XHT Peptides (stated 10 mg, batch RT101) tested 1 Oct 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
TB-500 from Kerui Peptide HongKong did not meet Finnrick's public standard
Finnrick's public record lists a TB-500 sample from Kerui Peptide HongKong (stated 5 mg, batch 07/2026 TB) tested 1 Oct 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Daily count
Finnrick published 31 tests on 2026-10-01: 19 met the public standard, 12 did not
On 2026-10-01 Finnrick published 31 independent laboratory tests across its vendor record. 19 met its public Purity Focus standard, 12 did not. Every result is public on Finnrick with the laboratory certificate behind it.
Wed, Sep 30, 2026
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 20 mg, batch March 2026) tested 30 Sep 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
5-Amino-1MQ from Shanghai ERP peptide Biotechnology did not meet Finnrick's public standard
Finnrick's public record lists a 5-Amino-1MQ sample from Shanghai ERP peptide Biotechnology (stated 50 mg, batch 990062) tested 30 Sep 2026 at Krause Analytical: purity 71.1%, measured 45.7 mg (-9% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for 5-Amino-1MQ→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 30 mg, batch Mar.2026) tested 30 Sep 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 30 mg) tested 30 Sep 2026 at PharmLabs:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Ipamorelin from Huaian Hanyou Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Ipamorelin sample from Huaian Hanyou Peptide (stated 10 mg) tested 30 Sep 2026 at Krause Analytical: purity 98.1%, measured 9.7 mg (-3% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from ChenHao BioHealth did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from ChenHao BioHealth (stated 30 mg, batch Ming063026) tested 30 Sep 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Ipamorelin from HK Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Ipamorelin sample from HK Peptides (stated 10 mg, batch June 28 2026) tested 30 Sep 2026 at Krause Analytical: purity 99.3%, measured 10.1 mg (+1% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Daily count
Finnrick published 30 tests on 2026-09-30: 26 met the public standard, 4 did not
On 2026-09-30 Finnrick published 30 independent laboratory tests across its vendor record. 26 met its public Purity Focus standard, 4 did not. Every result is public on Finnrick with the laboratory certificate behind it.
Tue, Sep 29, 2026
- Did not meet standard
GHK-Cu from Pura Peptides did not meet Finnrick's public standard
Finnrick's public record lists a GHK-Cu sample from Pura Peptides (stated 100 mg, batch GHKNP-71126) tested 29 Sep 2026 at Ichor Life Sciences: purity 99.9%, measured 140.1 mg (+40% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
GHK-Cu from NovaPeptide did not meet Finnrick's public standard
Finnrick's public record lists a GHK-Cu sample from NovaPeptide (stated 100 mg, batch 5EL-2026-0712) tested 29 Sep 2026 at Ichor Life Sciences:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
GHK-Cu from Apex Peptides did not meet Finnrick's public standard
Finnrick's public record lists a GHK-Cu sample from Apex Peptides (stated 100 mg, batch 340043) tested 29 Sep 2026 at Ichor Life Sciences: purity 100%, measured 142.537 mg (+43% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
GHK-Cu from Skye Peptides did not meet Finnrick's public standard
Finnrick's public record lists a GHK-Cu sample from Skye Peptides (stated 50 mg, batch GHK25-50-002) tested 29 Sep 2026 at Ichor Life Sciences: purity 100%, measured 77.92 mg (+56% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Daily count
Finnrick published 12 tests on 2026-09-29: 7 met the public standard, 4 did not
On 2026-09-29 Finnrick published 12 independent laboratory tests across its vendor record. 7 met its public Purity Focus standard, 4 did not, 1 could not be classified. Every result is public on Finnrick with the laboratory certificate behind it.
Fri, Sep 25, 2026
- Did not meet standard
Tirzepatide from Mai Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Mai Peptide (stated 20 mg, batch July 11, 2026) tested 25 Sep 2026 at Krause Analytical: purity 91.1%, measured 20.6 mg (+3% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
GHK-Cu from Lipeptides did not meet Finnrick's public standard
Finnrick's public record lists a GHK-Cu sample from Lipeptides (stated 50 mg, batch 02-13-2026) tested 25 Sep 2026 at Krause Analytical: purity 98.3%, measured 52.6 mg (+5% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from Peptide Boost Labs did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Peptide Boost Labs (stated 60 mg, batch Rt60) tested 25 Sep 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
BPC-157 from VIVA Biotechnology did not meet Finnrick's public standard
Finnrick's public record lists a BPC-157 sample from VIVA Biotechnology (stated 5 mg, batch 2026.6.24) tested 25 Sep 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Tirzepatide from Shanghai Leader Peptide Biotechnology did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Shanghai Leader Peptide Biotechnology (stated 20 mg, batch TP20260401) tested 25 Sep 2026 at Harrens Lab: purity 29.3%, measured 5.86 mg (-71% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from LP Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from LP Peptide (stated 30 mg, batch TR30260621) tested 25 Sep 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Sulan Pharma did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Sulan Pharma (stated 30 mg, batch SUL0801-001) tested 25 Sep 2026 at Harrens Lab: purity 43%, measured 12.89 mg (-57% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Mokemei Zhengzhou Biotechnology MKM did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Mokemei Zhengzhou Biotechnology MKM (stated 30 mg, batch Aug 15 2026) tested 25 Sep 2026 at Harrens Lab: purity 30%, measured 8.99 mg (-70% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Daily count
Finnrick published 4 tests on 2026-09-25: 3 met the public standard, 1 did not
On 2026-09-25 Finnrick published 4 independent laboratory tests across its vendor record. 3 met its public Purity Focus standard, 1 did not. Every result is public on Finnrick with the laboratory certificate behind it.
Thu, Sep 24, 2026
- Did not meet standard
Retatrutide from LP Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from LP Peptide (stated 10 mg, batch PED26050802) tested 24 Sep 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from Peptronix Bio PTB did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Peptronix Bio PTB (stated 30 mg, batch 3/15/2026) tested 24 Sep 2026 at Harrens Lab: purity 57.4%, measured 17.23 mg (-43% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from Fashion Pep did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Fashion Pep (stated 60 mg, batch XN-TR60012026-1) tested 24 Sep 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
5-Amino-1MQ from Yidan Biotech did not meet Finnrick's public standard
Finnrick's public record lists a 5-Amino-1MQ sample from Yidan Biotech (stated 50 mg, batch 50AM-2026-0622) tested 24 Sep 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for 5-Amino-1MQ→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 10 mg, batch Mar 2026) tested 24 Sep 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
TB-500 from Tianjin Eleli Technology Development did not meet Finnrick's public standard
Finnrick's public record lists a TB-500 sample from Tianjin Eleli Technology Development (stated 10 mg, batch 16.B.04.26) tested 24 Sep 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 30 mg, batch RT30 Mar2026) tested 24 Sep 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
NAD+ from ZePeptide did not meet Finnrick's public standard
Finnrick's public record lists a NAD+ sample from ZePeptide (stated 1000 mg) tested 24 Sep 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Epithalon from Mokemei Zhengzhou Biotechnology MKM did not meet Finnrick's public standard
Finnrick's public record lists a Epithalon sample from Mokemei Zhengzhou Biotechnology MKM (stated 50 mg, batch Jul.3,2026) tested 24 Sep 2026 at Krause Analytical: purity 98.7%, measured 43.9 mg (-12% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Tirzepatide from MT Meipept did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from MT Meipept (stated 40 mg, batch 01260822140L) tested 24 Sep 2026 at Harrens Lab: purity 95.7%, measured 38.28 mg (-4% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Novabio Research did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Novabio Research (stated 20 mg, batch RT20-2603-001) tested 24 Sep 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from ZLZ Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from ZLZ Peptide (stated 15 mg, batch 2026-06-10) tested 24 Sep 2026 at Harrens Lab: purity 40.4%, measured 6.06 mg (-60% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
NAD+ from ZLZ Peptide did not meet Finnrick's public standard
Finnrick's public record lists a NAD+ sample from ZLZ Peptide (stated 1000 mg) tested 24 Sep 2026 at Krause Analytical: purity 98.3%, measured 653 mg (-35% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from Hong Kong Meiliduo Technology Limited did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Hong Kong Meiliduo Technology Limited (stated 15 mg, batch July 15, 2026) tested 24 Sep 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from Laicuinuo LCN did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Laicuinuo LCN (stated 30 mg, batch JUNE012026) tested 24 Sep 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from HK Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from HK Peptides (stated 10 mg, batch jul 2026) tested 24 Sep 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
TB-500 from Orbitrex Peptides did not meet Finnrick's public standard
Finnrick's public record lists a TB-500 sample from Orbitrex Peptides (stated 10 mg, batch TB10826) tested 24 Sep 2026 at Krause Analytical: purity 98.1%, measured 9.32 mg (-7% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Retatrutide from Mokemei Zhengzhou Biotechnology MKM did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Mokemei Zhengzhou Biotechnology MKM (stated 60 mg, batch Aug 12 2026) tested 24 Sep 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Tirzepatide from Super Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Super Peptides (stated 30 mg, batch 01260822130L) tested 24 Sep 2026 at Harrens Lab: purity 44.2%, measured 13.27 mg (-56% against the stated amount). Reason recorded: purity below the standard's threshold; dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
GHK-Cu from Mokemei Zhengzhou Biotechnology MKM did not meet Finnrick's public standard
Finnrick's public record lists a GHK-Cu sample from Mokemei Zhengzhou Biotechnology MKM (stated 100 mg, batch 20260616-1) tested 24 Sep 2026 at Krause Analytical: purity 99%, measured 98.3 mg (-2% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
GHK-Cu from Laicuinuo LCN did not meet Finnrick's public standard
Finnrick's public record lists a GHK-Cu sample from Laicuinuo LCN (stated 100 mg, batch june 1 2026) tested 24 Sep 2026 at Krause Analytical: purity 99.9%, measured 53.8 mg (-46% against the stated amount). Reason recorded: dosage deviation out of range. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
- Did not meet standard
Tirzepatide from HK Peptides did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from HK Peptides (stated 60 mg, batch 12.6.25) tested 24 Sep 2026 at Harrens Lab: purity 75.9%, measured 45.56 mg (-24% against the stated amount). Reason recorded: purity below the standard's threshold. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Tirzepatide from Tianjin Finder Chemical TFC did not meet Finnrick's public standard
Finnrick's public record lists a Tirzepatide sample from Tianjin Finder Chemical TFC (stated 60 mg, batch 3/15/2026) tested 24 Sep 2026 at Harrens Lab:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Tirzepatide→
- Did not meet standard
Retatrutide from Mai Peptide did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Mai Peptide (stated 5 mg, batch fvl890) tested 24 Sep 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
- Did not meet standard
Retatrutide from Guangzhou Lengiuanhuang Cosmetics did not meet Finnrick's public standard
Finnrick's public record lists a Retatrutide sample from Guangzhou Lengiuanhuang Cosmetics (stated 30 mg, batch 258042) tested 24 Sep 2026 at Krause Analytical:. Reason recorded: identity not confirmed. Classified under Finnrick's public Purity Focus standard (purity at least 99.5%, fill within 35% of claim).
Source: Finnrick→ · Lyra Vital certificates for Retatrutide→
How to read this page
- What is Batch Watch?
- A dated record of independent research-peptide test results, vendor status changes and newly certified batches, assembled automatically from named public records and published as they appear. Each entry links the record it quotes so it can be checked without trusting this site.
- Where do the test results come from?
- Failed tests and daily counts are quoted from Finnrick, an independent peptide-testing platform that publishes its laboratory results and the certificate behind each one under a stated methodology. Vendor status lines are quoted from the same record. Lyra Vital's own entries are our certificates from Janoshik Analytical, each carrying the laboratory's verification key.
- Does a failed test mean a vendor is bad?
- No. It means one sample, on one date, did not meet the standard the testing platform applies. Vendors can and do pass other tests, and the platform publishes corrections when it changes a result. Read the linked record, including the vendor's full history, before drawing any conclusion.
- Why does Lyra Vital publish other vendors' results?
- Because the question every buyer actually has is whether a specific batch from a specific vendor is what it claims to be, right now, and the answer lives in public records that are scattered and easy to miss. Our own certificates sit in the same list, under the same rules, which is the only honest way to publish it.
Test results attributed to Finnrick are Finnrick’s published data under its public Purity Focus methodology; the laboratory certificate behind each is on their site, as are their corrections. Machine-readable feed: RSS. All products sold on this website are intended for research and identification purposes only. These products are not intended for human dosing, injection, or ingestion.